YY1 Binding Motif Upstream of Rep/Cap Increases AAV Yield and Full Capsids
Authors:
Preprint
Abstract
Adeno-associated virus (AAV) vectors are widely used in gene therapy, whereas low manufacturing efficiency and a large proportion of empty capsids are major obstacles. This study focused on the Yin Yang 1 (YY1) binding motif (YY1-motif) and investigated the effect of its presence or insertion upstream of the Replicase (Rep)/Capsid (Cap) gene on AAV vector production. We found that the YY1-motif incidentally presented in a Rep/Cap plasmid was associated with high vector production. We then designed several modified Rep/Cap (RC2) constructs. The YY1-motif insertion in front of Rep/Cap gene increased vector yield in a repeat-number-dependent manner, and similar effects were not observed with other promoters insertion. Furthermore, the insertion of the YY1-motif reduced the amount of Cap protein per the same amount of full particle in supernatants on multiple serotypes, indicating the improvement in the empty/full capsid ratio. The YY1-motif insertion did not affect the AAV vector infectivity. These results denote that the YY1-motif has a universal regulatory function that optimizes the Rep/Cap expression balance, and simultaneously improves the production efficiency and full particle formation of AAV vectors. This finding could contribute to the development of highly efficient and high-quality AAV manufacturing processes.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP23bm1323001)
- Japan Society for the Promotion of Science (20K07681)
- Japan Society for the Promotion of Science (26K02298)
- Takara Bio Inc. (Joint Research Fund)
This publication has 28 references indexed in Scilit:
- The evolving landscape of recombinant adeno-associated virus (rAAV) manufacturing: Engineering vector plasmids for upstream productionBiotechnology Advances, 2026
- Chronologically distributed transfection improves AAV2 and AAV2/8 capsid filling and reveals assembly schedule divergenceMolecular Therapy - Methods & Clinical Development, 2025
- AAV vector development, back to the futureMolecular Therapy, 2025
- Factors affecting rAAV titers during triple-plasmid transient transfection in HEK-293 cellsBiotechnology Letters, 2024
- Adeno-associated virus vector system controlling capsid expression improves viral quantity and qualityiScience, 2023
- Pharmacology of Recombinant Adeno-associated Virus ProductionMolecular Therapy - Methods & Clinical Development, 2018
- Molecular design for recombinant adeno-associated virus (rAAV) vector productionApplied Microbiology and Biotechnology, 2017
- YY1 Is a Structural Regulator of Enhancer-Promoter LoopsCell, 2017
- Rational plasmid design and bioprocess optimization to enhance recombinant adeno‐associated virus (AAV) productivity in mammalian cellsBiotechnology Journal, 2015
- Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effectsMolecular Therapy - Methods & Clinical Development, 2014